Treatment decisions for breast cancer are significantly influenced by subtype, which is determined from expression of estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), and the proliferation marker Ki67 [2]. Here, MKI67 is linked to breast carcinoma.